Cachexia: pathophysiology and clinical relevance.

By J. Morley, David R. Thomas, Margaret-Mary G. Wilson. American Journal of Clinical Nutrition, 2006

773 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Skeletal muscle performance and ageing (2017, neutral): “excessive weight loss in the setting of ongoing disease, usually with disproportionate muscle wasting).(6) Beyond muscle wasting, however, a”
Cachexia: a new definition. (2008, background): “Potential strategies for treating cachexia target skeletal muscle wasting in the presence of adequate nutrition.(32) Some potential pharmacological agents include androgens, selective androgen receptor modulators, antimyostatin drugs, growth hormone and insulin-like growth factor, and potential orex”
Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives (2008, background): “Cachexia results in both fat and muscle mass loss, but it accompanies chronic diseases such as cancer, AIDS or rheumatoid arthritis (17, 19).”
Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. (2010, background): “This has resulted in a measure of the systemic inflammatory response in the cancer patient being included in the definition of cancer cachexia [9,17,18].”